Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

26031 Drug of Abuse Survey without Confirmation, Urine

Drug of Abuse Survey without Confirmation, Urine
Test Code: DASWO
Synonyms/Keywords
​amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine
Test Components
​​Immunoassay screen for the following drug classes or method groups:  amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Useful For
​This is a screening assay performed on urine specimens and is designed to support medical, not forensic, purposes. The detection of drug classes listed in this survey is to be used for compliance monitoring and identification of abuse.  This test is intended to be used by a physician or trained provider and interpreted in the context of the patient's symptoms and history. Positive results are not definitive, and should be considered presumptive. Any presumptive positive results should be confirmed before the results are acted upon (confirmations need to be ordered separately). The advantage of this test is that it is low-cost to the patient, and in most cases will give enough information to determine if the patient is adhering to the guidelines of their particular program.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
​No ​Urine ​Sage urine collection container ​Sterile plastic container with no preservatives ​5 mL ​1.5 mL ​1.5 mL
Collection Processing Instructions
​​Immunoassay is useful in detecting truly negative samples. However, each immunoassay is more sensitive to some components of the drug class than others, and cross-reactivity of other substances can interfere or alter results. Therefore, this test is intended to be used by a physician or trained provider and interpreted in the context of the patient's symptoms and history.
Specimen Stability Information
​
​Specimen Type ​Temperature ​Time
​Urine ​ ​ ​Refrigerte (perferred) ​30 days
​Ambient ​7 days
​Frozen ​30 days
 
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield ​Monday through Friday ​1 day ​Beckman AU680 Clinical Chemistry System with Emit immunoassay
Test Information
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
​ 
This is a screening-only assay performed on urine specimens and is designed to support medical, not forensic, purposes. The detection of drug classes listed in this survey is to be used for compliance monitoring and identification of abuse.
 
This test recognizes the following drug classes utilizing immunoassay reagents: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine. Test includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
Immunoassay is useful in detecting truly negative samples. However, each immunoassay is more sensitive to some components of the drug class than others, and cross-reactivity of other substances can interfere or alter results. Therefore, this test is intended to be used by a physician or trained provider and interpreted in the context of the patient's symptoms and history.
 
Positive results are not definitive, and should be considered presumptive. Any presumptive positive results should be confirmed before the results are acted upon. The advantage of this test is that it is low-cost to the patient, and in most cases will give enough information to determine if the patient is adhering to the guidelines of their particular pain management program.
 
Specimens are kept for 6 business days from the screening date. If confirmation by GC or mass-spectrometry method confirmation is desired to accurately determine what drugs the patient is positive for, please call the laboratory at 93734 within this timeframe. If specimen is available, confirmation testing can be ordered at an additional charge. For specific details of what drugs are detected in each confirmation assay, please refer to the information provided with those specific test codes or inquire with the laboratory's technical staff before ordering.​
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Reference Range Information
Performing Location Reference Range
​Marshfield ​Negative
Interpretation
​​Current Cutoff Levels for Toxicology
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​80307 ​ ​1 ​Single Drug Class ​
Classification
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
​
Synonyms/Keywords
​amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiates, oxycodone, buprenorphine
Test Components
​​Immunoassay screen for the following drug classes or method groups:  amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Ordering Applications
Ordering Application Description
​COM ​Drug of Abuse Survey without Confirmation, Urine
​Centricity ​Drug of Abuse Survey without Confirmation, Urine
​Cerner ​Drug of Abuse Survey without Confirmation, Urine
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
​No ​Urine ​Sage urine collection container ​Sterile plastic container with no preservatives ​5 mL ​1.5 mL ​1.5 mL
Collection Processing
​​Immunoassay is useful in detecting truly negative samples. However, each immunoassay is more sensitive to some components of the drug class than others, and cross-reactivity of other substances can interfere or alter results. Therefore, this test is intended to be used by a physician or trained provider and interpreted in the context of the patient's symptoms and history.
Specimen Stability Information
​
​Specimen Type ​Temperature ​Time
​Urine ​ ​ ​Refrigerte (perferred) ​30 days
​Ambient ​7 days
​Frozen ​30 days
 
Useful For
​This is a screening assay performed on urine specimens and is designed to support medical, not forensic, purposes. The detection of drug classes listed in this survey is to be used for compliance monitoring and identification of abuse.  This test is intended to be used by a physician or trained provider and interpreted in the context of the patient's symptoms and history. Positive results are not definitive, and should be considered presumptive. Any presumptive positive results should be confirmed before the results are acted upon (confirmations need to be ordered separately). The advantage of this test is that it is low-cost to the patient, and in most cases will give enough information to determine if the patient is adhering to the guidelines of their particular program.
Test Components
​​Immunoassay screen for the following drug classes or method groups:  amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone, and buprenorphine.  Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
 
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well.  If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.
Reference Range Information
Performing Location Reference Range
​Marshfield ​Negative
Interpretation
​​Current Cutoff Levels for Toxicology
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Marshfield ​Monday through Friday ​1 day ​Beckman AU680 Clinical Chemistry System with Emit immunoassay
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​80307 ​ ​1 ​Single Drug Class ​
Classification
This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
​
For most current information refer to the Marshfield Laboratory online reference manual.